Euroopa Liit -
eesti -
EMA (European Medicines Agency)
firmagon
ferring pharmaceuticals a/s - degareliks - eesnäärmevähk - endokriinset ravi - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
Eesti -
eesti -
Adama
legacy® pro
adama - suspensioonikontsentraat - diflufenikaan + kloortoluroon + pendimetaliin - herbitsiidid
Eesti -
eesti -
Adama
trimmer® 50 sg
adama - vees dispergeeruvad graanulid - tribenuroon-metüül - herbitsiidid
Eesti -
eesti -
Adama
sultan® super
adama - suspensioonikontsentraat - kvinmerak + metasakloor - herbitsiidid
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
degarelix accord
accord healthcare s.l.u. - degarelix acetate - eesnäärmevähk - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.